Bicalutamide (‘Casodex’) 150 Mg as adjuvant to radical prostatectomy significantly increases progression-free survival in early prostate cancer: Evidence from a new analysis

Authors
Publication date
Publisher
'Elsevier BV'
Doi

    Abstract

    Abstract is not available.

      Similar works

      Full text

      thumbnail-image

      Available Versions

      Crossref

      redirect
      Last time updated on 05/12/2020